Expression of sex-determining region Y-box protein 2 in breast cancer and its clinical significance

Xuesong Feng, MS, Mingqian Lu, MD.

ABSTRACT

Sex-determining region Y-box protein 2 (SOX2) is an embryo transcription factor located on chromosome 3q26.3-q27. It plays an important role in the maintenance of differentiation and self-renewal of pluripotent stem cells. Studies have shown that SOX2 is associated with multiple cancers and is overexpressed in many different phenotypes of breast cancer. To study the relationship between SOX2 and clinicopathological parameters of breast cancer patients, we found that the expression of SOX2 was closely related to the increase in tumor size, histological grade, lymph node metastasis, and high invasiveness. Therefore, studies on the role of SOX2 in breast cancer may provide effective biomarkers and potential therapeutic targets for the diagnosis and treatment of breast cancer. This article will discuss the role of SOX2 in breast cancer, including its occurrence, invasion and metastasis, diagnosis and treatment, relapse, resistance, and prognosis.

Saudi Med J 2017; Vol. 38 (7): 685-690
doi: 10.15537/smj.2017.7.19372

From the The First College of Clinical Medical Science, China Three Gorges University Cancer Center & Yichang Central People’s Hospital, Yichang, China.
prognosis. The role of SOX2 in maintaining the self-renewal capacity of CSCs in breast cancer has been confirmed. Therefore, exploring the role of SOX2 in breast cancer may provide effective biomarkers for the diagnosis and treatment of breast cancer. This paper presents the role of SOX2 in breast cancer to provide effective biomarkers for the diagnosis and treatment of breast cancer, as well as a basis for further research on SOX2 and breast cancer.

1. Summary of SOX2. Sex-determining region Y-box protein 2 is an embryonic transcription factor located on chromosome 3q26.3-q27. Its encoded expression product, SOX2 protein, is constituted by 317 amino acids, and its molecular weight is 34.3 kDa. It plays an important role in the maintenance of the differentiation potential and self-renewal capacity of embryonic stem cells. Sex-determining region Y-box protein 2 has 3 main domains: the N-terminal domain, the high mobility group domain, and the transactivation domain. An increasing number of studies have shown that SOX2 is related to a variety of tumors. Silencing SOX2 can induce the transcription of p21Cip1 and p27Kip1, leading to cell cycle arrest and cell growth inhibition. Silencing the expression of SOX2 in lung squamous cell carcinoma results in cell suppression by up regulating the tumor suppressor BMP4. Knockdown of SOX2 in glioblastomas in immunodeficient mice reduces tumor cell proliferation and lost tumorigenicity. Sex-determining region Y-box protein 2 promotes cell proliferation in breast, prostate, and cervical cancers and involves the escape of apoptotic signals in prostate, gastric, and non-small cell lung cancer. These studies all suggested that SOX2 plays an important role in inhibiting cell apoptosis and promoting cell proliferation. Sex-determining region Y-box protein 2 mediates the aggressive and migratory phenotypes by activating MMP3, MMP2, and PI3K/AKT/mTOR, which indicates that SOX2 also plays a role in tumor invasion and metastasis. Results suggest that PI3K/Akt may play an important role in the expression of SOX2.

2. Sex-determining region Y-box protein 2 and breast cancer. The effect of SOX2 in breast cancer has gradually been identified with increasing study. Sex-determining region Y-box protein 2 is overexpressed in a variety of different phenotypes of breast cancer. In breast cancer, SOX2 has been found in sporadic basaloid carcinomas and in several early postmenopausal cancers. Lengerke et al evaluated SOX2 expression in primary tumors of 95 postmenopausal breast cancer patients, and they reported its association with various early postmenopausal breast cancer and lymph node metastases. Rodriguez-Pinilla et al showed high expression of SOX2 in basal-like breast cancer based on statistics. When they investigated the association of SOX2 with sporadic basal-like breast tumors, 43.3% showed SOX2 immunoreactivity, whereas SOX2 expression was only found in 13.3% of HER2-positive tumors and 10.6% of luminal tumors by immunohistochemical analysis of 226 sporadic node-negative infiltrative breast cancers. They reported that SOX2 expression is directly related to tumor size, CK5/6, epidermal growth factor receptor, and vimentin expression when SOX2 expression is upregulated. Zheng et al reported that SOX2 expression is closely related to tumor size, histological grade, lymph node metastasis, and high invasive triple negative phenotype by analyzing the relationship between SOX2 and clinical pathological parameters of patients with breast cancer. They believed that the detection of SOX2 expression might have great value in determining the diagnosis and prognosis of patients with breast cancer. Huang et al found that SOX2 is associated with the expression status of tumor-negative hormone receptor, high proliferative index, and neuroendocrine marker expression; moreover, it plays a role in poorly differentiated tumors. Sex-determining region Y-box protein 2 has different prognostic significance in 5 kinds of breast cancer: basal-like, luminal A and B, HER2+, and normal breast-like carcinomas.

2.1 SOX2 and the development of breast cancer. To study the role of SOX2 in the development of breast tumors, Chen et al found that overexpression of SOX2 increases the population of S + G2/M phase cells and decreases the G0/ G1 phase cell population. They used functional acquisition experiments and loss of function experiments to examine the effect of SOX2 overexpression or low expression on cell cycle regulation in breast cancer cells via retroviral-mediated overexpression and low expression strategies. Similarly,
using siRNA to decrease the expression of SOX2 results in cell arrest at the G0/ G1 phase. This finding indicates that the accumulation of G0/G1 cells is specifically correlated with the loss of the SOX2 gene and SOX2 protein. Thus, SOX2 might promote cell proliferation and tumorigenesis of breast cancer by accelerating the G1/S transition of cell cycle, and SOX2 and β-catenin both regulate the transcription of cyclin D1 (CCND1) in breast cancer. Cyclin D1 may also play a certain role in the development of the disease. However, the specific mechanisms still need to be further explored.

### 2.2 SOX2 with the invasion and metastasis of breast cancer

The recruitment of tumor-associated macrophages promotes the metastasis of breast cancer. Sex-determining region Y-box protein 2-positive breast cancer cells can regulate the secretion of many cytokines such as MIP-1a/ CCL3 and ICAM. It also regulates the activation of the NF-κB and STAT3 signaling pathway to play an important role in the recruitment of tumor-associated macrophages. Li et al. reported similar associations in a meta-analysis of the relationship between SOX2 and clinicopathological parameters in patients with breast cancer. Increasing SOX2 expression in early breast cancer might promote tumor metastasis. Although there is no conclusive evidence that SOX2 is associated with lymph node metastasis, recent studies have demonstrated that SOX2-positive patients present significantly higher lymph node metastasis rates than those with SOX2-negative disease. Michifuri et al. stated that SOX2 is essential for invasion and proliferation of breast cancer, and SOX2-positive cancer cells have a higher ability and probability to transfer to the lymph nodes than SOX2-negative cancer cells; in addition, down regulation of SOX2 expression significantly reduces angiogenesis and lymphangiogenesis of breast cancer. Chinese studies have shown that SOX2 might promote angiogenesis and lymphangiogenesis by promoting vascular endothelial growth factor A secretion to affect tumor lymph node metastasis. These studies suggested that SOX2 plays a role in breast cancer metastasis through a variety of mechanisms. Sex-determining region Y-box protein 2 indicates poor prognosis, so it is a viable marker for prognosis in patients with breast cancer.
At present, the problems of SOX2 and invasive breast cancer remain controversial. Fang et al. found that downregulation of SOX2 expression significantly increases invasiveness of breast cancer such as MCF7 and ZR751 in a study on the relationship between SOX2 and breast cancer cell invasion. Sex-determining region Y-box protein 2 inhibits the invasiveness of breast cancer cells through a mechanism that is dependent on Twist-1 and the transcriptional activity of SOX2. The latest Chinese studies revealed that SOX2-positive cells suggest high tumor invasion and lead to tumor lymph node metastasis by promoting blood vessels and lymphangiogenesis. Experimental results show that SOX2 plays a certain role in angiogenesis. The relationship between SOX2 and invasive ability of breast cancer cells needs further confirmation.

2.3 SOX2 with the diagnosis and treatment of breast cancer. Li et al. detected the regulation effect of SOX2 in the expression of FOXA1 by reverse transcription polymerase chain reaction (RT-PCR) and Western blot. Their results revealed that SOX2 acts as a negative upstream regulator of the FOXA1 (Forkhead Box A1) gene and inhibits FOXA1 expression. They also found significantly higher tumor incidence because SOX2 and FOXA1 were both expressed abnormally compared with that in which only a single gene was expressed abnormally in invasive breast cancer. Immunohistochemical staining further revealed that SOX2 and FOXA1 demonstrates complementation in the diagnosis of human breast cancer. Therefore, SOX2 and FOXA1 can be used as effective markers for the diagnosis of breast cancer. The use of FOXA1, as a cofactor of SOX2, can improve the diagnostic efficiency of breast cancer.

In addition, studies found that SOX2-related serum, SOX2 autoantibody (SOX2-Ab), can be used as a serum marker of breast cancer. Sex-determining region Y-box protein 2-Abs was first reported in 2012. It is a noninvasive and simple serological marker for the diagnosis and prognosis of breast cancer. Schaefer et al. found that Ser/Thr-kinase AKT is an upstream regulator of SOX2 protein, and ectopic expression of SOX2 enhances the ability of clones of tumor cells and restores the cellular tumorigenicity of cells that were inhibited by AKT inhibitors in vivo. AKT inhibitors can effectively inhibit the growth of tumor stem cells with SOX2 expression on which conventional chemotherapeutic agents usually act. Therefore, AKT inhibitors can inhibit the expression of SOX2 protein. Novel treatment methods for breast cancer may be obtained by studying effective AKT inhibitors. In a recent study, Liu et al. demonstrated that a new SOX2-mediated regulatory axis plays an important role in the proliferation, invasion, and metastasis of breast cancer cells, thereby providing a novel direction for the treatment of breast cancer.

2.4 SOX2 with the recurrence and resistance of breast cancer. Sex-determining region Y-box protein 2 is associated with early recurrence of breast cancer. Finicelli et al. observed the effect of SOX2 on early recurrence in patients with breast cancer via multivariate analysis. The risk of recurrence with SOX2-positive disease (82%) was higher than that in SOX2-negative disease (42%) in 117 breast cancer samples. Therefore, patients with SOX2-positive disease will relapse earlier than patients with SOX2-negative disease.

Drug resistance of breast cancer has always been a clinical problem. CSCs play a role in tumor radiotherapy and chemotherapy resistance. Tamoxifen, an estrogen receptor antagonist, is the basic therapy of patients with breast cancer. Piva et al. found that tamoxifen-resistant cells are enriched in tumor stem/progenitor cells, and they express high levels of stem cell marker SOX2. The sensitivity of tamoxifen is negatively related to the ectopic expression of SOX2. The tumor stem/progenitor cell population decreases and sensitivity to tamoxifen is restored if the expression of SOX2 gene is knocked out. Compared with patients who were successful with endocrine therapy, the SOX2...
level was higher in primary tumors of patients with failure to endocrine therapy. Gene expression profiles showed that the Wnt signaling pathway is activated in SOX2-expressing cells. It can restore sensitivity of drug-resistant cells to tamoxifen through inhibition of Wnt signaling. These results indicate that the development of tamoxifen resistance is mediated by SOX2-dependent activation of Wnt signaling in cancer stem/progenitor cells.

In conclusion. The role of SOX2 in maintaining the self-renewal capacity of CSCs in breast cancer has been confirmed, and it is overexpressed in different phenotypes of breast cancer. The expression of SOX2 is closely related to the increase in tumor size, histological grade, lymph node metastasis, and high invasiveness. Therefore, studies on the role of SOX2 in breast cancer may provide effective biomarkers and potential therapeutic targets for the diagnosis and treatment of early-stage breast cancer.

With the gradual recognition of the role of SOX2 in tumors, the specific mechanisms of SOX2 in tumor occurrence, invasion and metastasis, diagnosis and treatment, relapse, resistance, and prognosis are becoming research hotspots. Breast cancer remains the leading cause of women cancer death in the world. The global incidence of breast cancer are more than 20% and mortality 10%. It is a kind of malignant tumor with extensive genomics research. The recurrence, metastasis, drug resistance, and other issues of breast cancer seriously affect the quality of life of patients. Therefore, studies on the mechanism of the development of SOX2 in human breast cancer are crucial. Further research on SOX2 may determine the specific mechanism of SOX2 in breast cancer to provide novel techniques for the detection, diagnosis, treatment, and prognosis of breast cancer. The intervention of the mechanism of SOX2 action will provide a new therapeutic target for the treatment of breast cancer, as well as an appropriate detection index for the prognosis of breast cancer.

References

1. Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk DJ, Guan DL, et al. Expression of the embryonic stem cell marker SOX2 in human breast cancer. *BMC Cancer* 2011; 11: 42.
2. Mateos A, et al. CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. *Cancer Res* 2012; 72: 40-48.
3. Gomez S, et al. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. *BMC Cancer* 2011; 11: 42.
4. Power D G, Kelsen D P, Shah M A. Advanced gastric cancer--slow but steady progress. *Cancer Treat Rev* 2010; 36: 384-392.
5. Herreros-Villanueva M, Zhang J S, Koenig A, Abel EV, Smyrk TC, Gamble JR, et al. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. *Oncogenesis* 2013; 2: e61.
6. Neumann J, Bahr F, Horst D, Kriegel L, Engels J, Luque RM, et al. SOX2 expression correlates with lymph-node metastases and distant spread in right-sided colon cancer. *BMC Cancer* 2011; 11: 518.
7. Guzel E, Karatos O F, Duz M B, Solak M, Ittmann M, Ozen M. Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer. *Prostate* 2014; 74: 1498-1505.
8. Ren Z H, Zhang C P, Ji T. Expression of SOX2 in oral squamous cell carcinoma and the association with lymph node metastasis. *Oncol Lett* 2016; 11: 1973-1979.
9. Lee SH, Oh SY, Do SI, Lee HJ, Kang HJ, Rho YS, et al. SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma. *Br J Cancer* 2014; 111: 2122-2130.
10. Maier S, Wilbertz T, Braun M, Scheble V, Reischl M, Mikut R, et al. SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. *Hum Pathol* 2011; 42: 1078-1088.
11. Kokalj VN, Cizmarevic B, Zagorac A, Zagradinić B, Lanišnik B. An evaluation of SOX2 and hTERC gene amplifications as screening markers in oral and oropharyngeal squamous cell carcinomas. *Mol Cytogenet* 2014; 7: 5.
12. Loris E, Eguia A, Lopez-Arriballaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, et al. SOX2 expression in breast tumours and activation in breast cancer stem cells. *Oncogene* 2012; 31: 1354-1365.
13. Kauhold S, Garban H, Bonavida B. Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication. *J Exp Clin Cancer Res* 2016; 35:84.
14. Kelberman D, Rizzoti K, Avillon A, Bitner-Glindzicz M, Cianfarani S, Collins J, et al. Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. *J Clin Invest* 2006; 116: 2442-2455.
15. Fang WT, Fan CC, Li SM, Jang TH, Lin HP, Shih NY, et al. Downregulation of a putative tumor suppressor BMP4 by SOX2 promotes growth of lung squamous cell carcinoma. *Int J Cancer* 2014; 135: 809-819.
16. Gangemi R M, Girotto F, Marubbi D, Perera M, Capra MC, Malatesta P, et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. *Stem Cells* 2009; 27: 40-48.
17. Yang N, Hui L, Wang Y, Yang H, Jiang X. SOX2 promotes the migration and invasion of laryngeal cancer cells by induction of MMP-2 via the PI3K/Akt/mTOR pathway. *Oncol Rep* 2014; 31: 2651-2659.
21. Rodriguez-Pinilla S M, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L, et al. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 2007; 20: 474-481.

22. Lengerke C, Fehm T, Kurth R, Neubauer H, Scheble V, Müller F, et al. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer 2011; 11:42.

23. Zheng Y, Qin B, Li F, Xu S, Wang S, Li L, et al. Clinicopathological significance of Sox2 expression in patients with breast cancer: a meta-analysis. Int J Clin Exp Med 2015; 8: 22382-22392.

24. Huang Y H, Luo M H, Ni Y B, Tsang JY, Chan SK, Lui PC, et al. Increased SOX2 expression in less differentiated breast carcinomas and their lymph node metastases. Histopathology 2014; 64: 494-503.

25. Perou C M, Sorlie T, Eisen M B, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.

26. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008; 283: 17969-17978.

27. Mou W, Xu Y, Ye Y, Chen S, Li X, Gong K, et al. Expression of Sox2 in breast cancer cells promotes the recruitment of M2 macrophages to tumor microenvironment. Cancer Lett 2015; 358: 115-123.

28. Li X, Xu Y, Chen Y, Chen S, Jia X, Sun T, et al. SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/beta-catenin signal network. Cancer Lett 2013; 336: 379-389.

29. Shima H, Kutomi G, Satomi F, Maeda H, Hirohashi Y, Hasegawa T, et al. SOX2 and ALDH1 as predictors of operable breast cancer. Anticancer Res 2016; 36: 2945-2953.

30. Michifuri Y, Hirohashi Y, Torigoe T, Miyazaki A, Kobayashi J, Sasaki T, et al. High expression of ALDH1 and SOX2 diffuse staining pattern of oral squamous cell carcinomas correlates to lymph node metastasis. Pathol Int 2012; 62: 684-689.

31. Han Zenglei, Wang Lina, Kong Qingnuan, WEI Hongjun; CHEN Hua; HUANG Weiqing. The relationship between lymphangiogenesis and SOX2 and vascular endothelial growth factor-C in breast cancer. Chinese Medicine Review 2015; (10): 23-26.

32. Wu F, Ye X, Wang P, Jung K, Wu C, Douglas D, et al. Sox2 suppresses the invasiveness of breast cancer cells via a mechanism that is dependent on Twist1 and the status of Sox2 transcription activity. BMC Cancer 2013; 13: 317.

33. Han Zenglei, Yang Yanhua, Kong Qingnuan, WEI Hongjun; CHEN Hua; HUANG Weiqing. The relationship between SOX2 expression and angiogenesis in breast cancer and its significance. Chinese Journal of Diagnostic Pathology 2016; (01): 47-49.

34. Li X, Chen S, Sun T, Xu Y, Chen Y, Liu Y, et al. The transcriptional regulation of SOX2 on FOXA1 gene and its application in diagnosis of human breast and lung cancers. Clin Lab 2014; 60: 909-918.

35. Sun Y, Zhang R, Wang M, Zhang Y, Qi J, Li J. SOX2 autoantibodies as noninvasive serum biomarker for breast carcinoma. Cancer Epidemiol Biomarkers Prev 2012; 21: 2043-2047.

36. Schaefer T, Wang H, Mir P, Konantz M, Pereboom TC, Paczulla AM, et al. Molecular and functional interactions between AKT and SOX2 in breast carcinoma. Oncotarget 2015; 6: 43540-43556.

37. Liu K, Xie F, Gao A, Zhang R, Zhang L, Xiao Z, et al. SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis. Mol Cancer 2017; 16: 62.

38. Finicelli M, Benedetti G, Squillaro T, Pistilli B, Marcellusi A, Mariani P, et al. Expression of stemness genes in primary breast cancer tissues: the role of SOX2 as a prognostic marker for detection of early recurrence. Oncotarget 2014; 5: 9678-9688.

39. Piva M, Domenici G, Iriondo O, Rabano M, Simões BM, Comaills V, et al. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med 2014; 6: 66-79.